SleepFixSam — wow. I've been looking for this exact info for weeks.

Slightly tangential to MASH prevalence in GLP-1 but claudia_zurich reminded me — has anyone else noticed changes in their alcohol tolerance?

I know it is not exactly on-topic but it seems related enough to ask here rather than starting a new thread. Apologies if this has been covered — I did search first.

Thanks for sharing this, claudia_zurich. A few questions about your MASH prevalence in experience:

1. What dose worked best for you?
2. How long before you noticed appetite suppression kicking in?
3. Did your endo have any specific recommendations about MASH prevalence?

I am in a similar boat and trying to learn from others' experiences before my next appointment.

OP here — wow, did not expect this much response! Thank you all for the thoughtful replies on MASH prevalence in GLP-1.

To answer matt_MKE: I get my labs done through Quest every 3 months.

Quick update: my latest labs came back even better. Thanks again for the evidence-based discussion — this is exactly why I posted in a science-based community. 🙏

Relevant to MASH prevalence in GLP-1 users — here is my latest bloodwork comparison:

Key improvements: A1C 7.2% → 5.3%, triglycerides 227 → 97 mg/dL, hsCRP 6.0 → 0.9 mg/L. All on tirzepatide for 7 months.

The inflammatory marker drop is what impresses me most. Consistent with the SELECT trial's cardiovascular findings.